Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 5
2002 15
2003 25
2004 35
2005 42
2006 43
2007 51
2008 65
2009 45
2010 52
2011 48
2012 43
2013 36
2014 40
2015 46
2016 52
2017 38
2018 39
2019 54
2020 37
2021 48
2022 40
2023 37
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

848 results

Results by year

Filters applied: . Clear all
Page 1
Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features.
Ribeiro H, Rodrigues I, Napoleão L, Lira L, Marques D, Veríssimo M, Andrade JP, Dourado M. Ribeiro H, et al. Biomed Pharmacother. 2022 Jun;150:112958. doi: 10.1016/j.biopha.2022.112958. Epub 2022 Apr 19. Biomed Pharmacother. 2022. PMID: 35453005 Free article. Review.
A narrative review of papers published from January 2011 to December 2021, after a literature search in selected databases using the terms "pharmacokinetics", "ibuprofen", "diclofenac", "acemetacin", "naproxen", "etodolac" and "etoricoxib" was performed. From 828 articles …
A narrative review of papers published from January 2011 to December 2021, after a literature search in selected databases using the terms " …
Etoricoxib.
Cochrane DJ, Jarvis B, Keating GM. Cochrane DJ, et al. Drugs. 2002;62(18):2637-51; discussion 2652-3. doi: 10.2165/00003495-200262180-00006. Drugs. 2002. PMID: 12466002 Review.
Etoricoxib had similar efficacy to diclofenac in patients with osteoarthritis of the knee. ...Etoricoxib had similar efficacy to indomethacin in a study in patients with acute gout, and single-dose etoricoxib had similar efficacy to naproxen sodium in a study …
Etoricoxib had similar efficacy to diclofenac in patients with osteoarthritis of the knee. ...Etoricoxib had similar efficacy …
Etoricoxib.
Matsumoto AK, Cavanaugh PF Jr. Matsumoto AK, et al. Drugs Today (Barc). 2004 May;40(5):395-414. Drugs Today (Barc). 2004. PMID: 15319795 Review.
Etoricoxib (Arcoxia, Merck & Co., Inc.) is a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in pain and inflammation. ...This review summarizes the published preclinical and clinical data relevant to the use of etoricoxib in clinical practic …
Etoricoxib (Arcoxia, Merck & Co., Inc.) is a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in pain and infl …
UNCOMMON ETORICOXIB.
Wenckus CS. Wenckus CS. J Am Dent Assoc. 2019 Sep;150(9):735. doi: 10.1016/j.adaj.2019.07.014. J Am Dent Assoc. 2019. PMID: 31439200 No abstract available.
MORE ON ETORICOXIB.
Marek CL, Hellstein JW. Marek CL, et al. J Am Dent Assoc. 2019 Sep;150(9):735-736. doi: 10.1016/j.adaj.2019.07.015. J Am Dent Assoc. 2019. PMID: 31439199 No abstract available.
Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis.
van Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA. van Walsem A, et al. Arthritis Res Ther. 2015 Mar 19;17(1):66. doi: 10.1186/s13075-015-0554-0. Arthritis Res Ther. 2015. PMID: 25879879 Free PMC article. Review.
This study compared the efficacy, safety, and tolerability of diclofenac, ibuprofen, naproxen, celecoxib, and etoricoxib for patients with pain caused by osteoarthritis (OA) or rheumatoid arthritis (RA). ...Major upper GI events with diclofenac were lower compared to napro …
This study compared the efficacy, safety, and tolerability of diclofenac, ibuprofen, naproxen, celecoxib, and etoricoxib for patients …
[Etoricoxib (Arcoxia)].
Leclercq P, Malaise MG. Leclercq P, et al. Rev Med Liege. 2004 May;59(5):345-9. Rev Med Liege. 2004. PMID: 15270001 Free article. Review. French.
Etoricoxib (Arcoxia) is a novel non steroidal anti-inflammatory drug (NSAID) that selectively inhibits the inducible form of cyclo-oxygenase (COX), COX-2. Etoricoxib has a higher COX-1/COX-2 selectivity ratio than the other COX-2-selective NSAIDs as rofecoxib, valde …
Etoricoxib (Arcoxia) is a novel non steroidal anti-inflammatory drug (NSAID) that selectively inhibits the inducible form of cyclo-ox …
Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study.
Arfè A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, Schink T, Garbe E, Herings R, Straatman H, Schade R, Villa M, Lucchi S, Valkhoff V, Romio S, Thiessard F, Schuemie M, Pariente A, Sturkenboom M, Corrao G; Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium. Arfè A, et al. BMJ. 2016 Sep 28;354:i4857. doi: 10.1136/bmj.i4857. BMJ. 2016. PMID: 27682515 Free article.
Risk of heart failure doubled for diclofenac, etoricoxib, indomethacin, piroxicam, and rofecoxib used at very high doses (2 defined daily dose equivalents), although some confidence intervals were wide. Even medium doses (0.9-1.2 defined daily dose equivalents) of indometh …
Risk of heart failure doubled for diclofenac, etoricoxib, indomethacin, piroxicam, and rofecoxib used at very high doses (2 defined d …
Anaphylaxis to Etoricoxib.
Couto M, López-Salgueiro R, Gaspar Â. Couto M, et al. J Investig Allergol Clin Immunol. 2018 Apr;28(2):135-136. doi: 10.18176/jiaci.0221. J Investig Allergol Clin Immunol. 2018. PMID: 29661743 Free article. No abstract available.
Clinical pharmacology of etoricoxib.
Capone ML, Tacconelli S, Patrignani P. Capone ML, et al. Expert Opin Drug Metab Toxicol. 2005 Aug;1(2):269-82. doi: 10.1517/17425255.1.2.269. Expert Opin Drug Metab Toxicol. 2005. PMID: 16922642 Review.
Moreover, recent studies evidence its efficacy in patients with ankylosing spondylitis. In the Etoricoxib Diclofenac Gastrointestinal Evaluation study performed in patients with OA, etoricoxib significantly reduced the rate of discontinuation by 50% due to gastroint …
Moreover, recent studies evidence its efficacy in patients with ankylosing spondylitis. In the Etoricoxib Diclofenac Gastrointestinal …
848 results